文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

特瑞普利单抗联合化疗治疗复发或转移性鼻咽癌:JUPITER-02随机临床试验

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial.
PubMed 文献 · JAMA · 2023-01-01

JUPITER-02是一项国际多中心随机双盲3期研究,纳入289例复发或转移性鼻咽癌患者,比较特瑞普利单抗联合吉西他滨-顺铂与安慰剂联合化疗的疗效。结果显示,特瑞普利单抗组中位无进展生存期显著延长(21.4 vs 8.2个月;HR 0.52),总生存期也显著改善(HR 0.63;中位总生存期未达到 vs 33.7个月),安全性总体可控,但免疫相关不良事件更常见。

要点

  • 特瑞普利单抗联合吉西他滨-顺铂一线治疗复发或转移性鼻咽癌,中位无进展生存期21.4个月,显著优于安慰剂组的8.2个月(HR 0.52)。
  • 总生存期显著改善(HR 0.63;双侧P=0.008),特瑞普利单抗组中位总生存期未达到,安慰剂组为33.7个月。
  • 特瑞普利单抗组免疫相关不良事件(54.1% vs 21.7%)及3级及以上免疫相关不良事件(9.6% vs 1.4%)更常见,但总体安全性可控。

核心结论

  • 在复发或转移性鼻咽癌的一线治疗中,特瑞普利单抗联合吉西他滨-顺铂较单纯化疗显著改善无进展生存期和总生存期,且安全性可控,支持将该联合方案作为该人群的新标准治疗。

研究设计与样本

  • JUPITER-02是一项国际、多中心、随机、双盲3期研究,在鼻咽癌流行地区(中国大陆、台湾和新加坡)开展。
  • 2018年11月10日至2019年10月20日期间,从35个参与中心纳入289例复发或转移性鼻咽癌患者,均未在复发/转移阶段接受过全身化疗。
  • 患者按1:1随机接受特瑞普利单抗(240 mg,n=146)或安慰剂(n=143)联合吉西他滨-顺铂,最多6个周期,随后特瑞普利单抗或安慰剂维持治疗,直至疾病进展、不可耐受的毒性或完成2年治疗。

主要发现

  • 在最终无进展生存期分析中,特瑞普利单抗组中位无进展生存期为21.4个月,安慰剂组为8.2个月(HR 0.52,95%CI 0.37-0.73)。
  • 中位生存随访36.0个月时,特瑞普利单抗组总生存期较安慰剂组显著改善(HR 0.63,95%CI 0.45-0.89;双侧P=0.008)。
  • 特瑞普利单抗组中位总生存期未达到,安慰剂组为33.7个月。
  • 在高和低PD-L1表达亚组中均观察到一致的总生存期获益,倾向特瑞普利单抗。
  • 两组全部不良事件、3级及以上不良事件和致死性不良事件发生率相似;但特瑞普利单抗组导致停药的不良事件(11.6% vs 4.9%)、免疫相关不良事件(54.1% vs 21.7%)和3级及以上免疫相关不良事件(9.6% vs 1.4%)更常见。

关键数值与推荐

  • 无进展生存期:特瑞普利单抗组中位21.4个月 vs 安慰剂组8.2个月(HR 0.52,95%CI 0.37-0.73)。
  • 总生存期:特瑞普利单抗组中位未达到 vs 安慰剂组33.7个月(HR 0.63,95%CI 0.45-0.89;双侧P=0.008)。
  • 导致停药的不良事件发生率:特瑞普利单抗组11.6% vs 安慰剂组4.9%。
  • 免疫相关不良事件发生率:特瑞普利单抗组54.1% vs 安慰剂组21.7%;3级及以上免疫相关不良事件:9.6% vs 1.4%。

临床怎么用

  • 作者认为,特瑞普利单抗联合吉西他滨-顺铂可作为复发或转移性鼻咽癌患者的新标准治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is the current standard of care for the first-line treatment of recurrent or metastatic NPC (RM-NPC). OBJECTIVE: To determine whether toripalimab in combination with gemcitabine-cisplatin will significantly improve progression-free survival and overall survival as first-line treatment for RM-NPC, compared with gemcitabine-cisplatin alone. DESIGN, SETTING, AND PARTICIPANTS: JUPITER-02 is an international, multicenter, randomized, double-blind phase 3 study conducted in NPC-endemic regions, including mainland China, Taiwan, and Singapore. From November 10, 2018, to October 20, 2019, 289 patients with RM-NPC with no prior systemic chemotherapy in the RM setting were enrolled from 35 participating centers. INTERVENTIONS: Patients were randomized (1:1) to receive toripalimab (240 mg [n = 146]) or placebo (n = 143) in combination with gemcitabine-cisplatin for up to 6 cycles, followed by maintenance with toripalimab or placebo until disease progression, intolerable toxicity, or completion of 2 years of treatment. MAIN OUTCOME: Progression-free survival as assessed by a blinded independent central review. Secondary end points included objective response rate, overall survival, progression-free survival assessed by investigator, duration of response, and safety. RESULTS: Among the 289 patients enrolled (median age, 46 [IQR, 38-53 years; 17% female), at the final progression-free survival analysis, toripalimab treatment had a significantly longer progression-free survival than placebo (median, 21.4 vs 8.2 months; HR, 0.52 [95% CI, 0.37-0.73]). With a median survival follow-up of 36.0 months, a significant improvement in overall survival was identified with toripalimab over placebo (hazard ratio [HR], 0.63 [95% CI, 0.45-0.89]; 2-sided P = .008). The median overall survival was not reached in the toripalimab group, while it was 33.7 months in the placebo group. A consistent effect on overall survival, favoring toripalimab, was found in subgroups with high and low PD-L1 (programmed death-ligand 1) expression. The incidence of all adverse events, grade 3 or greater adverse events, and fatal adverse events were similar between the 2 groups. However, adverse events leading to discontinuation of toripalimab or placebo (11.6% vs 4.9%), immune-related adverse events (54.1% vs 21.7%), and grade 3 or greater immune-related adverse events (9.6% vs 1.4%) were more frequent in the toripalimab group. CONCLUSIONS AND RELEVANCE: The addition of toripalimab to chemotherapy as first-line treatment for RM-NPC provided statistically significant and clinically meaningful progression-free survival and overall survival benefits compared with chemotherapy alone, with a manageable safety profile. These findings support the use of toripalimab plus gemcitabine-cisplatin as the new standard of care for this patient population. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03581786.

来源:JAMA,查看原文。版权归原作者所有。

引用

  1. Mai HQ, Chen QY, Chen D, et al. Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. JAMA. 2023. PMID: 38015220. doi:10.1001/jama.2023.20181

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。